Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517761 · ClinicalTrials.gov registry record · NA
Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries
A NA study of Craniocervical Injuries, sponsored by Regenexx.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT03517761 is a NA study of Craniocervical Injuries that is actively recruiting participants, run by Regenexx. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03517761, a NA study of Craniocervical Injuries, is actively recruiting participants, sponsored by Regenexx.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness of using anterior approach through the posterior oropharynx for treating alar and transverse ligament injuries with bone marrow concentrate for patients with craniocervical junction (CCJ) instability.
Conditions Studied
Interventions
- BIOLOGICAL Bone Marrow Concentrate treatment
- OTHER Sham Control
Study Locations (1)
Colorado
- Ehren Dodson - Broomfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-03-23 |
| Est. Completion | 2030-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03517761
The ClinicalTrials.gov registry entry for NCT03517761 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regenexx, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Craniocervical Injuries appearing as the primary indexed condition, and to 2 interventions - of which Bone Marrow Concentrate treatment is the first listed.
NCT03517761 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03517761 about?
NCT03517761 is a clinical study titled "Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries". The purpose of this study is to evaluate the effectiveness of using anterior approach through the posterior oropharynx for treating alar and transverse ligament injuries with bone marrow concentrate for patients with craniocervical junction (CCJ) instability.
What is the current status of trial NCT03517761?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2018-03-23. Estimated completion is 2030-12.
What conditions does trial NCT03517761 study?
This clinical trial studies the following conditions: Craniocervical Injuries.
What interventions are being tested in trial NCT03517761?
The interventions under investigation include: Bone Marrow Concentrate treatment (BIOLOGICAL), Sham Control (OTHER).
Who is sponsoring clinical trial NCT03517761?
This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03517761 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.